open access

Vol 11, No 6 (2016)
Case Reports
Published online: 2017-01-17
Get Citation

Idarucizumab: a new level of anticoagulation therapy. Description of the treatment of bleeding in 93-year-old patient

Kamilla Katarzyna Wesołowska, Agnieszka Woronowicz-Chróściel, Maciej Kluk, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2016.0114
·
Folia Cardiologica 2016;11(6):554-556.

open access

Vol 11, No 6 (2016)
Case Reports
Published online: 2017-01-17

Abstract

Idarucizumab is a fragment of a monoclonal antibody that has high affinity for dabigatran etexilate and binds to it, causing a rapid suppression of its anticoagulant effect. Idarucizumab infusion in patients treated with dabigatran etexilate quickly restores systemic blood coagulation and enables the re-formation of fibrin that plays a key role in the mechanism of blood coagulation.

Abstract

Idarucizumab is a fragment of a monoclonal antibody that has high affinity for dabigatran etexilate and binds to it, causing a rapid suppression of its anticoagulant effect. Idarucizumab infusion in patients treated with dabigatran etexilate quickly restores systemic blood coagulation and enables the re-formation of fibrin that plays a key role in the mechanism of blood coagulation.

Get Citation

Keywords

idarucizumab, dabigatran, antidote, gastrointestinal bleeding

About this article
Title

Idarucizumab: a new level of anticoagulation therapy. Description of the treatment of bleeding in 93-year-old patient

Journal

Folia Cardiologica

Issue

Vol 11, No 6 (2016)

Pages

554-556

Published online

2017-01-17

DOI

10.5603/FC.2016.0114

Bibliographic record

Folia Cardiologica 2016;11(6):554-556.

Keywords

idarucizumab
dabigatran
antidote
gastrointestinal bleeding

Authors

Kamilla Katarzyna Wesołowska
Agnieszka Woronowicz-Chróściel
Maciej Kluk
Beata Wożakowska-Kapłon

References (1)
  1. Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators, RE-LY Investigators, RE-LY study group, RE-LY investigators, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl